These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 30142655)

  • 21. Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.
    Gehlen H; Fisch J; Merle R; Trachsel DS
    J Vet Sci; 2021 Sep; 22(5):e64. PubMed ID: 34553515
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
    Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R
    Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pergolide dosing compliance and factors affecting the laboratory control of equine pituitary pars intermedia dysfunction.
    Hague N; Durham AE; Menzies-Gow NJ
    Vet Rec; 2021 Jul; 189(1):e142. PubMed ID: 33759215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Equine Cushing syndrome (ECS). Case report, review of its diagnosis and therapy and substantial differences from Cushing syndrome in dogs].
    Fey K; Jonigkeit E; Moritz A
    Tierarztl Prax Ausg G Grosstiere Nutztiere; 1998 Feb; 26(1):41-7. PubMed ID: 9626747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The oral glucose test predicts laminitis risk in ponies fed a diet high in nonstructural carbohydrates.
    Meier AD; de Laat MA; Reiche DB; Pollitt CC; Walsh DM; McGree JM; Sillence MN
    Domest Anim Endocrinol; 2018 Apr; 63():1-9. PubMed ID: 29172109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of plasma ACTH, alpha-melanocyte-stimulating hormone, and insulin concentrations during various photoperiods in clinically normal horses and ponies and those with pituitary pars intermedia dysfunction.
    Beech J; Boston RC; McFarlane D; Lindborg S
    J Am Vet Med Assoc; 2009 Sep; 235(6):715-22. PubMed ID: 19751169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.
    McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE
    J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of cortisol concentration in the tears of horses and ponies with pituitary pars intermedia dysfunction.
    Hart KA; Kitchings KM; Kimura S; Norton NA; Myrna KE
    Am J Vet Res; 2016 Nov; 77(11):1236-1244. PubMed ID: 27805438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioactive and immunoreactive adrenocorticotropin in normal equine pituitary and in pituitary tumors of horses with Cushing's disease.
    Orth DN; Nicholson WE
    Endocrinology; 1982 Aug; 111(2):559-63. PubMed ID: 6284484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
    Spelta CW; Axon JE
    Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proopiolipomelanocortin peptides in normal pituitary, pituitary tumor, and plasma of normal and Cushing's horses.
    Wilson MG; Nicholson WE; Holscher MA; Sherrell BJ; Mount CD; Orth DN
    Endocrinology; 1982 Mar; 110(3):941-54. PubMed ID: 6276164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis.
    Kellon EM; Gustafson KM
    Open Vet J; 2022; 12(4):511-518. PubMed ID: 36118716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004.
    Rohrbach BW; Stafford JR; Clermont RS; Reed SM; Schott HC; Andrews FM
    J Vet Intern Med; 2012; 26(4):1027-34. PubMed ID: 22524260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutics for Equine Endocrine Disorders.
    Durham AE
    Vet Clin North Am Equine Pract; 2017 Apr; 33(1):127-139. PubMed ID: 28190613
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.
    McGowan TW; Pinchbeck GP; McGowan CM
    Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of pituitary gland anatomy and histopathologic findings in clinically normal horses and horses and ponies with pituitary pars intermedia adenoma.
    van der Kolk JH; Heinrichs M; van Amerongen JD; Stooker RC; in de Wal LJ; van den Ingh TS
    Am J Vet Res; 2004 Dec; 65(12):1701-7. PubMed ID: 15631037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case of pituitary adrenocorticotropin-dependent Cushing's syndrome in the horse.
    Moore JN; Steiss J; Nicholson WE; Orth DN
    Endocrinology; 1979 Mar; 104(3):576-82. PubMed ID: 220013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of a pony with Cushing's disease.
    Okada T; Yuguchi K; Kiso Y; Morikawa Y; Nambo Y; Oikawa M; Sasaki F
    J Vet Med Sci; 1997 Aug; 59(8):707-10. PubMed ID: 9300369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of pituitary pars intermedia dysfunction in practice: A clinical audit.
    Steel NL; Ireland JL; McGowan CM
    Vet J; 2022 Nov; 289():105899. PubMed ID: 36162625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of pergolide mesylate on adrenocorticotrophic hormone responses to exogenous thyrotropin releasing hormone in horses.
    Durham AE
    Vet J; 2022 Jul; 285():105831. PubMed ID: 35477010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.